Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis (1996)

Peer-Reviewed Study · WHO Informal Working Group on Echinococcosis (WHO-IWGE); Bulletin of the World Health Organization 1996;74(3):231-242 · 1996

WHO's 1996 treatment guidelines for human echinococcosis: mebendazole at 40-50 mg/kg per day for at least 3-6 months, given in three divided doses after meals.

The usual oral dosage of mebendazole is 40-50mg per kg per day for at least 3-6 months.

235 (PDF page 6 of the file)

WHO's 1996 treatment guidelines for human echinococcosis: mebendazole at 40-50 mg/kg per day for at least 3-6 months, given in three divided doses after meals. Guideline/consensus report, not a trial: no patient denominator of its own; built from two WHO meetings (Besancon 1992, Al-Ain 1994). Country: WHO (Geneva), multinational panel. Dose recorded: 'Mebendazole (Vermox, 500mg, Janssen, Belgium) is given as 500-mg tablets in daily doses of 40-50mg/kg body weight (in three divided doses after meals)' with target plasma level >250 nmol/L (74 ng/ml) after 4 weeks (French text, p.239). Adverse effects section: 'The adverse effects of benzimidazoles include hepatotoxicity (transient increase of aminotransferases) (19, and Annex), neutropenia, thrombocytopenia and alopecia.' No frequency rates given. Funder: WHO. Conflicts: none declared (no disclosure section in 1996). Product named: Vermox 500 mg, Janssen, Belgium. Comparator: none (guideline). Quote is from the scanned PDF text layer; PDF page 6 of the file carries printed page 235. Quote checked against pdftotext default-mode extraction, not -layout, because the two-column layout interleaves.